|
MedChemExpress
d galactose injections D Galactose Injections, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/D-Galactose/pmc12852416-58-9-23 Average 95 stars, based on 1 article reviews
d galactose injections - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Galectin Therapeutics
lentivirus ![]() Lentivirus, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/lentivirus/pmc07998015-91-5-39 Average 90 stars, based on 1 article reviews
lentivirus - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Galectin Therapeutics
galectin-1 ![]() Galectin 1, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/galectin+1/10__1074_slash_jbc__m112__418848-91-13-4 Average 90 stars, based on 1 article reviews
galectin-1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
MedChemExpress
d galactose ![]() D Galactose, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/D-Galactose/pm40768898-96-21-23 Average 93 stars, based on 1 article reviews
d galactose - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
GL Sciences
optic multimode inlet 4 ![]() Optic Multimode Inlet 4, supplied by GL Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/optic4+system/pmc05857133-143-18-23 Average 90 stars, based on 1 article reviews
optic multimode inlet 4 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
gapdh ![]() Gapdh, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/HMOX2%2FHO-2+Rabbit+mAb/pm37463048-339-50-30 Average 93 stars, based on 1 article reviews
gapdh - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Sinopharm ltd
d-galactose ![]() D Galactose, supplied by Sinopharm ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/d+galactose/pmc10852738-104-9-10 Average 90 stars, based on 1 article reviews
d-galactose - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
ATCC
b16f10 melanoma cells ![]() B16f10 Melanoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/B16-F10/pmc02881890-87-3-19 Average 99 stars, based on 1 article reviews
b16f10 melanoma cells - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
Galectin Therapeutics
lectin galectin-1 ![]() Lectin Galectin 1, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/lectin+galectin+1/pm10814697-54-23-8 Average 90 stars, based on 1 article reviews
lectin galectin-1 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Tokyo Chemical Industry
d-galactose ![]() D Galactose, supplied by Tokyo Chemical Industry, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/d+galactose/pm29962322-50-12-17 Average 90 stars, based on 1 article reviews
d-galactose - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Proteintech
antibodies against p62 ![]() Antibodies Against P62, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/P62%2FSQSTM1+Antibody/pmc12365738-38-0-40 Average 96 stars, based on 1 article reviews
antibodies against p62 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
d galactose ![]() D Galactose, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/d+galactose+injections/D-Galactose/10__33899_slash_ijvs__2022__134092__2342-57-15-16 Average 93 stars, based on 1 article reviews
d galactose - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Cell Death & Disease
Article Title: Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis
doi: 10.1038/s41419-021-03603-0
Figure Lengend Snippet: A Schematic diagram showing the functional exploration of C3ar1 and galectin-3 in IPF using lentivirus and galectin-3 interference (shRNA group), respectively. Alternatively, antagonists were used to block the binding affinity of C3a and galectin-3 (antagonist group). B , C Body weight and survival of IPF mice with galectin-3 shRNA lentivirus ( B ) (LV C3ar1 shRNA and LV galectin-3 shRNA, n = 5) or antagonists ( C ) (SB290157: antagonist of C3ar1; GB1107: antagonist of GB1107, n = 6). D , E HE and Masson’s trichrome staining of mouse lung sections following lentivirus or antagonist treatments. Scale bar = 500 μm (global view) or 50 μm (detailed view). F Semiquantitative morphological index/scoring of lung sections. The grade ranges from 1 (normal) to 8 (complete fibrosis). n = 30 for each group; * p < 0.05, ** p < 0.01, *** p < 0.001.
Article Snippet: After nasal intubation to inject
Techniques: Functional Assay, shRNA, Blocking Assay, Binding Assay, Staining
Journal: JCI insight
Article Title: AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice.
doi: 10.1172/jci.insight.170199
Figure Lengend Snippet: Figure 1. Systemic gene transfer fails to rescue muscle pathology after short-term treatment at a low vector dose. (A) Experimental design: 3.5-month-old KO mice received a single injection of systemic vector (SYS; n = 5) at a dose of 0.5 × 1013 vg/kg. Age-matched wild-type (WT) and untreat- ed Gaa–/– (KO) mice were used as controls. Muscle samples were collected 1 month (mo) after dosing. (B) Western blot analyses of whole muscle lysates with anti-human GAA antibody. Gapdh was used as a loading control. Graph shows GAA activity in muscle tissues from WT, KO, and SYS-treated KO mice. (C) Glycogen content in muscle tissues across the groups. (D) PAS-stained sections of gastrocnemius muscle; PAS-positive material (small dots) is seen in all fibers from KO mice; some fibers (or parts of a fiber) from SYS-treated KO mice appear normal (asterisks). Bars: 50 μm. (E) Western blot analy- ses of whole muscle lysates with the indicated antibodies. No significant decrease in the levels of lysosomal/autophagosomal markers is seen in treated compared to untreated KO. Statistical significance was determined by 1-way ANOVA and unpaired 2-tailed Student’s t test. Graphs represent mean ± SD. *P < 0.05; **P < 0.01; ****P < 0.0001.
Article Snippet: The following primary antibodies (all diluted 1:1,000) were used: total and phosphorylated AMPK (2535; T172 5831; rabbit monoclonal) and total and nonphosphorylated 4EBP1 (4923; T46 9644, rabbit monoclonal) were from
Techniques: Plasmid Preparation, Injection, Western Blot, Control, Activity Assay, Staining
Journal: JCI insight
Article Title: AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice.
doi: 10.1172/jci.insight.170199
Figure Lengend Snippet: Figure 3. Systemic gene transfer rescues cardiac and diaphragmatic pathology after short-term treatment at an intermediate dose. (A) Experimental design: 3-month-old KO mice received a single injection of systemic vector (SYS; n = 3) at a dose of 2.5 × 1013 vg/kg. Age-matched wild-type (WT) and untreated Gaa–/– (KO) mice were used as controls. Muscle samples were collected 1 month (mo) after dosing. (B) Western blot analyses of cardiac muscle and diaphragm lysates with anti-human GAA antibody. Gapdh was used as a loading control. (C) GAA activity in the heart and diaphragm far exceeds the WT levels. (D and E) PAS-stained sections of cardiac muscle and the diaphragm; PAS-positive material is abundant in the heart and diaphragm of a KO mouse; the pathology and glycogen content are fully normalized in the heart of SYS-treated KO; inset shows PAS-positive residual glycogen in some cells in the diaphragm despite the treatment. Bars: 50 μm. For inset in E, original magnification, ×2. Statistical significance was determined by 1-way ANOVA. Graphs represent mean ± SD. ****P < 0.0001.
Article Snippet: The following primary antibodies (all diluted 1:1,000) were used: total and phosphorylated AMPK (2535; T172 5831; rabbit monoclonal) and total and nonphosphorylated 4EBP1 (4923; T46 9644, rabbit monoclonal) were from
Techniques: Injection, Plasmid Preparation, Western Blot, Control, Activity Assay, Staining
Journal: JCI insight
Article Title: AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice.
doi: 10.1172/jci.insight.170199
Figure Lengend Snippet: Figure 5. Muscle glycogen, autophagosomal-lysosomal markers, and mTORC1/AMPK signaling return to near normal after short-term systemic gene transfer at an intermediate vector dose. (A) Experimental design: 3-month-old KO mice received a single injection of systemic (SYS n = 4) or liver-secreted (LS n = 4) vector at a dose of 2.5 × 1013 vg/kg. Age-matched wild-type (WT) and untreated Gaa–/– (KO) mice were used as controls. Muscle samples were collected 1 month (mo) after dosing. (B) Western blot analyses of whole muscle lysates with anti-human GAA antibody. The 110 kDa GAA precursor protein is clearly detectable after LS treatment. Gapdh was used as a loading control. Graph shows GAA activity in muscle tissues from WT, untreated KO, and KO treated with SYS or LS vector. (C) Glycogen content in muscle tissues across the groups. (D and E) Western blot analyses of whole muscle lysates with the indicated antibodies. Statistical significance was determined by 1-way ANOVA. Graphs represent mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Article Snippet: The following primary antibodies (all diluted 1:1,000) were used: total and phosphorylated AMPK (2535; T172 5831; rabbit monoclonal) and total and nonphosphorylated 4EBP1 (4923; T46 9644, rabbit monoclonal) were from
Techniques: Plasmid Preparation, Injection, Western Blot, Control, Activity Assay
Journal: JCI insight
Article Title: AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice.
doi: 10.1172/jci.insight.170199
Figure Lengend Snippet: Figure 9. Systemic gene transfer reverses muscle pathology in old KO mice. (A) Experimental design: 9-month-old KO mice received a single injection of SYS (n = 8) vector at a dose of 2.5 × 1013 vg/kg. Age-matched (15.5-month-old) wild-type (WT) and 13.5-month-old untreated Gaa–/– (KO) mice were used as con- trols. Muscle samples were collected 7 months after dosing. (B) SYS-treated KO mice appear healthy for their age group; a 13.5-month-old KO mouse shows profound muscle weakness and wasting; see Supplemental Videos 1 and 2. (C) Western blot analyses of whole muscle lysates with anti-human GAA antibody. Gapdh was used as a loading control. Graph shows GAA activity in muscle tissues from WT, untreated KO, and SYS-treated KO mice. (D) Glycogen content in muscle tissues across the groups. (E) PAS-stained sections of gastrocnemius muscle from WT, KO, and SYS-treated mice; muscle fibers from SYS-treated mice appear normal. Bars: 50 μm. (F) Western blot analyses of whole muscle lysates with the indicated antibodies. (G) Immunostaining of single fibers with markers for lysosomes (LAMP1; green), autophagosomes (LC3; red), and nuclei (Hoechst dye; blue); muscle fibers from SYS-treated KO mice are free from autophagic buildup. Bright autofluorescent particles consist of lipofuscin, a typical feature in patients and in a KO model of the disease (87); autophagic buildup in 13.5-month-old untreated KO occupies large portions of the fibers (the image shows projection view produced from 6 consecutive optical sections (Z-stack). Bars: 20 μm. (H) Muscle strength was assessed using grip strength test after treatment. Statistical significance was determined by 1-way ANOVA and unpaired 2-tailed Student’s t test. Data presented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Article Snippet: The following primary antibodies (all diluted 1:1,000) were used: total and phosphorylated AMPK (2535; T172 5831; rabbit monoclonal) and total and nonphosphorylated 4EBP1 (4923; T46 9644, rabbit monoclonal) were from
Techniques: Injection, Plasmid Preparation, Western Blot, Control, Activity Assay, Staining, Immunostaining, Produced
Journal: JCI insight
Article Title: AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice.
doi: 10.1172/jci.insight.170199
Figure Lengend Snippet: Figure 10. Systemic gene transfer restores glycogen accumulation to normal levels in the brain after long-term treatment at an intermediate vector dose. (A) Experimental design. Young (3-month-old) and old (8- to 9-month-old) KO mice received a single injection of SYS (n = 3 young; n = 7 old) or LS (n = 3 young; n = 4 old) vector at a dose of 2.5 × 1013 vg/kg. Age-matched wild-type (WT) and untreated Gaa–/– (KO) mice were used as controls. The samples were collected 7–8 months after dosing. (B) Western blot analyses of whole brain lysates with anti-human GAA antibody. The 110 kDa GAA precursor pro- tein is the predominant form in the brains of LS-treated KO mice. Gapdh was used as a loading control. (C and D) Graphs show GAA activity and glycogen content in brain tissues across the groups in young and old animals. (E) PAS-stained sections of brain tissues (cerebellum and hindbrain) across the groups in old animals; brain sections from SYS-treated mice appear normal; brain sections from LS-treated mice show glycogen storage in neurons and glial cells. Bars: 50 μm. Statistical significance was determined by 1-way ANOVA. Graphs represent mean ± SD. **P < 0.01; ***P < 0.001; ****P < 0.0001.
Article Snippet: The following primary antibodies (all diluted 1:1,000) were used: total and phosphorylated AMPK (2535; T172 5831; rabbit monoclonal) and total and nonphosphorylated 4EBP1 (4923; T46 9644, rabbit monoclonal) were from
Techniques: Plasmid Preparation, Injection, Western Blot, Control, Activity Assay, Staining
Journal: BMC Cancer
Article Title: Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy
doi: 10.1186/1471-2407-10-200
Figure Lengend Snippet: PAF-receptor antagonist, WEB2170, inhibits melanoma growth and in combination with chemotherapy improves the survival of melanoma-bearing mice . (A) B16F10 melanoma cells (5 × 10 5 ) were injected s.c. into C57BL/6 mice and tumours were measured daily with a caliper. Tumour volume was calculated by the formula: maximum diameter × (minimum diameter) 2 × 0.52. WEB2170 (5 mg/Kg) was given i.p. 30 minutes before the tumour followed by daily injections for 12 days. DTIC (40 μg/animal) was injected i.p. every 3 days after tumour implantation. Data represent the mean ± SEM of tumour volume (n = 5). (B) The Kaplan-Mayer survival curve. For the survival experiments, WEB2170-treatment was given once a day and DTIC every 3 days for 35 days or until the animals died (n = 8-9). Statistical analyses were performed using the log rank test and differences were considered significant at p < 0.05. (*) p < 0.05 compared to PBS group.
Article Snippet: Tumours derived from
Techniques: Injection
Journal: BMC Cancer
Article Title: Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy
doi: 10.1186/1471-2407-10-200
Figure Lengend Snippet: Combined therapy with PAF-receptor antagonist and dacarbazine targets both tumour and microenvironmental elements . B16F10 melanoma cells (5 × 10 5 ) were injected s.c. into C57BL/6 mice and after 12 days the tumours were excised and processed for immunohistochemistry analysis with antibodies to caspase-3 (A) , COX-2 (B) , CD34 (C) or galectin-3 (D) . Alternatively, spleens of animals of the very same groups and of naïve mice were analysed for the presence of galectin-3-expressing cells in the white pulp (E) . WEB2170 (5 mg/Kg) was given 30 min before the tumour followed by daily injections for 12 days. DTIC (40 μg/animal) was injected i.p. every 3 days after tumour implantation. Morphometric analyses were performed using Eclipse Net software (Nikon). Grids were projected onto tissue sections and the number of grid intersections that overlaid an immunoreactive cell was counted. Results are expressed as the % of area occupied by the cells expressing a given marker (frequency). Data represent the mean ± SEM of positive cells (n = 10). Statistical analyses were performed using ANOVA and SNK (Student Neumans-Keuls test) and differences were considered significant at p < 0.05. ( * ) p < 0.05 comparing treated with non-treated (PBS) groups.
Article Snippet: Tumours derived from
Techniques: Injection, Immunohistochemistry, Expressing, Software, Marker
Journal: BMC Cancer
Article Title: Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy
doi: 10.1186/1471-2407-10-200
Figure Lengend Snippet: PAF-R is expressed within the tumour microenvironment . (A) The presence of PAF-R was evaluated by FACS analysis in cell suspensions from B16F10-derived tumours (histograms on the left). Examples from either mock (PBS) or dacarbazine (DTIC)-treated animals are illustrated. The histograms shown represent the negative control (ctl) and reactivity with the antibody to PAF-R. Cells from within the tumours stained positively with the antibody to PAF-R. The histogram on the right represents the absence of reactivity for the antibody to PAF-R in B16F10 cells grown in vitro . (B) Immunohistochemistry of B16F10-derived tumours using the same antibody to PAF-R, showing specific reactivity to a few cells infiltrating the tumours, consistent with the notion that only a subpopulation of cells within the tumour microenvironment express the PAF-R (arrow indicates a stained cell).
Article Snippet: Tumours derived from
Techniques: Derivative Assay, Negative Control, Staining, In Vitro, Immunohistochemistry
Journal: Molecular Medicine Reports
Article Title: ER-α36 knockdown is associated with lysosomal dysfunction and proliferation inhibition in liver cancer cells
doi: 10.3892/mmr.2025.13649
Figure Lengend Snippet: ER-α36 knockdown blocks autophagic flux and degradation. Expression of p62 in stably transfected liver cancer cells with different levels of ER-α36 expression: (A) Representative western blots and (B) quantitative analysis. (C) Confocal microscopy images of liver cancer cells with and without ER-α36 knockdown infected with pmCherry-enhanced GFP-LC3b adenovirus (scale bar, 10 µm) and (D) quantification of yellow and red puncta. (E) Levels of LC3-II and LC3-I assessed by western blotting in transfected liver cancer cells treated with or without CQ (20 µM) for 24 h, and (F) quantitative analysis of the LC3-II/LC3-I ratio. (G) Western blots of ubiquitinated proteins in the transfected liver cancer cells and (H) quantitative analysis of Ub levels. **P<0.01. ER, estrogen receptor; GFP, green fluorescence protein; LC3, microtubule-associated protein 1 light chain 3; CQ, chloroquine; Ub, ubiquitin; Sh36, transfected with ER-α36 specific short hairpin RNA expression vector; Vector, transfected with empty vector.
Article Snippet:
Techniques: Knockdown, Expressing, Stable Transfection, Transfection, Western Blot, Confocal Microscopy, Infection, Fluorescence, Ubiquitin Proteomics, shRNA, Plasmid Preparation
Journal: Molecular Medicine Reports
Article Title: ER-α36 knockdown is associated with lysosomal dysfunction and proliferation inhibition in liver cancer cells
doi: 10.3892/mmr.2025.13649
Figure Lengend Snippet: ER-α36 knockdown suppresses the malignant proliferation of liver cancer cells and induces lysosomal membrane permeabilization. (A) Representative images of liver tumors from nude mice intrahepatically injected with HepG2 cells expressing different ER-α36 levels, harvested at 28 days post-injection. (B) Quantitative analysis of liver tumor volume, liver weight, body weight and the ratio of liver weight to body weight. (C) Representative H&E staining images showing pathological karyomitosis changes. Scale bar, 50 µm. (D) Immunohistochemical staining of LC3, p62, LAMP1 and Ki67 with corresponding IOD values. Scale bar, 50 µm. (E) Immunofluorescence staining of Gal-3 in the tumors formed from the transfected HepG2 cells. Scale bar, 10 µm. (F) Western blotting results showing the levels of LC3-II and LC3-II, p62, LAMP1, p-AKT and t-AKT in the tumors, and (G) quantitative analyses of the LC3-II/LC3-I and p-AKT/t-AKT ratios, and p62 and LAMP1 expression levels. β-actin was used as the internal loading control. Data are presented as the mean ± SEM. **P<0.01. ER, estrogen receptor; H&E, hematoxylin and eosin; LC3, microtubule-associated protein 1 light chain 3; LAMP1, lysosome-associated membrane protein 1; Gal-3, galectin-3; IOD, integrated optical density; p-, phosphorylated; t-, total; Sh36, transfected with ER-α36 specific short hairpin RNA expression vector; Vector, transfected with empty vector.
Article Snippet:
Techniques: Knockdown, Membrane, Injection, Expressing, Staining, Immunohistochemical staining, Immunofluorescence, Transfection, Western Blot, Control, shRNA, Plasmid Preparation